search
Back to results

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Primary Purpose

Schizophrenia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
SM-13496 (lurasidone HCl)
SM-13496 (lurasidone HCl)
Placebo
Risperidone
Sponsored by
Sumitomo Pharma Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia

Eligibility Criteria

18 Years - 74 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  • Patient meets DSM-IV criteria for schizophrenia.
  • Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.
  • Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.

Main Exclusion Criteria:

  • Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.
  • Patient has Parkinson's disease.
  • Patient has a history or complication of malignancy.

Sites / Locations

  • Japan: 67 sites
  • Korea: 14 sites
  • Taiwan: 11 sites

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Placebo Comparator

Active Comparator

Arm Label

SM-13496 (lurasidone HCl) 40mg

SM-13496 (lurasidone HCl) 80mg

Placebo

Risperidone

Arm Description

SM-13496 40 mg was administered orally once daily.

SM-13496 80mg was administered orally once daily.

Placebo was administered orally twice daily.

Risperidone was administered orally twice daily.

Outcomes

Primary Outcome Measures

Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.

Secondary Outcome Measures

Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)
The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Change From Baseline in the PANSS Negative Subscales at Week 6
The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)
The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a study participant who was taking a medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.
Proportion of Participants With TEAEs Leading to Discontinuation
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Proportion of participants with treatment-emergent adverse events. An adverse event was considered serious if it met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Was considered to be an important medical event.

Full Information

First Posted
June 11, 2008
Last Updated
April 9, 2022
Sponsor
Sumitomo Pharma Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00711269
Brief Title
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Official Title
Randomized, Placebo-controlled, Double-blind, Parallel-group, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase III Study>
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
June 27, 2008 (Actual)
Primary Completion Date
April 27, 2010 (Actual)
Study Completion Date
April 27, 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sumitomo Pharma Co., Ltd.

4. Oversight

5. Study Description

Brief Summary
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
460 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SM-13496 (lurasidone HCl) 40mg
Arm Type
Experimental
Arm Description
SM-13496 40 mg was administered orally once daily.
Arm Title
SM-13496 (lurasidone HCl) 80mg
Arm Type
Experimental
Arm Description
SM-13496 80mg was administered orally once daily.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo was administered orally twice daily.
Arm Title
Risperidone
Arm Type
Active Comparator
Arm Description
Risperidone was administered orally twice daily.
Intervention Type
Drug
Intervention Name(s)
SM-13496 (lurasidone HCl)
Intervention Description
Lurasidone HCl: 40 mg/day
Intervention Type
Drug
Intervention Name(s)
SM-13496 (lurasidone HCl)
Intervention Description
Lurasidone HCl: 80 mg/day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Type
Drug
Intervention Name(s)
Risperidone
Primary Outcome Measure Information:
Title
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 (LOCF)
Description
The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.
Time Frame
Baseline and Week 6 [Last Observation Carried Forward (LOCF)]
Secondary Outcome Measure Information:
Title
Change From Baseline in the PANSS Positive Subscales at Week 6 (LOCF)
Description
The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time Frame
Baseline and Week 6 (LOCF)
Title
Change From Baseline in the PANSS Negative Subscales at Week 6
Description
The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.
Time Frame
Baseline and Week 6 (LOCF)
Title
Change From Baseline in the PANSS General Psychopathology Subscales at Week 6 (LOCF)
Description
The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.
Time Frame
Baseline and Week 6 (LOCF)
Title
Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)
Description
Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a study participant who was taking a medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.
Time Frame
From Baseline to up to 8 weeks
Title
Proportion of Participants With TEAEs Leading to Discontinuation
Time Frame
From Baseline to up to 8 weeks
Title
Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Description
Proportion of participants with treatment-emergent adverse events. An adverse event was considered serious if it met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required in-patient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability/incapacity; Was a congenital anomaly/birth defect; Was considered to be an important medical event.
Time Frame
From Baseline to up to 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Patient meets DSM-IV criteria for schizophrenia. Patient is 18 or older but younger than 75 years of age on the day of signing informed consent. Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent. Main Exclusion Criteria: Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus. Patient has Parkinson's disease. Patient has a history or complication of malignancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Drug Development Division
Organizational Affiliation
Sumitomo Pharma Co., Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Japan: 67 sites
City
Tokyo, Etc.
Country
Japan
Facility Name
Korea: 14 sites
City
Seoul, Etc.
Country
Korea, Republic of
Facility Name
Taiwan: 11 sites
City
Taipei, Etc.
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

We'll reach out to this number within 24 hrs